^
    Back
    Association details:
    Biomarker:MUC1 elevation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Chemother Pharmacol
    Title:

    Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer

    Published date:
    08/22/2023
    Excerpt:
    In ICI monotherapy for NSCLC without IP, elevated serum KL-6 levels were associated with poorer outcomes.
    DOI:
    https://doi.org/10.1007/s00280-023-04573-0